What causes tolerance to nitroglycerin? The 100 year old mystery continues (Q43537958)

24 November 2017

0 references

What causes tolerance to nitroglycerin? The 100 year old mystery continues (English)

1 reference

24 November 2017

M Packer

1

1 reference

PubMed ID

1976662

24 November 2017

language of work or name

English

0 references

publication date

1 October 1990

1 reference

Journal of the American College of Cardiology

24 November 2017

1 reference

24 November 2017

16

1 reference

24 November 2017

4

1 reference

24 November 2017

932-935

1 reference

Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Nitroglycerin Tolerance in Vitro: Effect on cGMP Turnover in Vascular Smooth Muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Development of tolerance to glyceryl trinitrate in an isolated human peripheral vein and its relation to cyclic GMP metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Determinants of in vitro nitroglycerin tolerance induction and reversal: influence of dose regimen, nitrate-free period, and sulfhydryl supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Prevention and reversal of nitrate tolerance in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Potentiation of the hemodynamic effects of acutely administered nitroglycerin by methionine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Altered spectrum of nitroglycerin action in long-term treatment: nitroglycerin-specific venous tolerance with maintenance of arterial vasodepressor potency.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

A preliminary double-blind study of intravenous nitroglycerin in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Dependence of arterial pressure on intravascular volume in treated hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

Limited usefulness of intermittent nitroglycerin patches in stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2810%2980343-2

7 January 2021

10.1016/S0735-1097(10)80343-2

Identifiers

DOI

1 reference

24 November 2017

1 reference

PubMed ID

1976662